Pregled bibliografske jedinice broj: 586965
Nonalcoholic fatty liver disease/steatohepatitis : Epidemiology, pathogenesis, clinical presentation and treatment
Nonalcoholic fatty liver disease/steatohepatitis : Epidemiology, pathogenesis, clinical presentation and treatment // Digestive diseases, 30 (2012), 2; 158-162 doi:10.1159/000336669 (recenziran, pregledni rad, stručni)
CROSBI ID: 586965 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Nonalcoholic fatty liver disease/steatohepatitis : Epidemiology, pathogenesis, clinical presentation and treatment
(Nonalcoholic fatty liver disease/steatohepatitis: Epidemiology, pathogenesis, clinical presentation and treatment)
Autori
Milić, Sandra ; Štimac, Davor
Izvornik
Digestive diseases (0257-2753) 30
(2012), 2;
158-162
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, stručni
Ključne riječi
diagnostic procedures; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; treatment
Sažetak
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic hepatic disorder in Western countries, with a prevalence of 20-30%. NAFLD comprises 'silent liver disease', in which simple steatosis is the only histological finding and which is benign in course, and nonalcoholic steatohepatitis, which is characterized by hepatocellular injury and inflammation with or without fibrosis. NAFLD is clinically important, because even benign fatty liver can progress to steatohepatitis in many patients, which can lead to liver cirrhosis and its complications and hepatocellular carcinoma. NAFLD is a hepatic manifestation of metabolic syndrome ; it is closely related to other clinical features of metabolic syndrome, and thus to cardiovascular morbidity. There are several different noninvasive techniques for formal diagnosis and follow-up, but liver biopsy remains the gold standard. The most important therapeutic strategies include lifestyle changes, including changes in dietary habits aimed at weight loss and blood pressure regulation, with a consequent decrease in insulin resistance. For some patients with NAFLD/nonalcoholic steatohepatitis, pharmacological treatment is the best option, although further studies are needed to confirm its efficacy and tolerability.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Napomena
Metabolic and Autoimmune Diseases of the Digestive System.
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE